ISOPP CAPhO 2025 Symposium: Refractory Multiple Myeloma Developments 1-2-3-4-5-6-7th Relapse - Natco Pharma (Canada) Inc. On-Demand Symposium

The presentation provides guidance on managing multiple myeloma, particularly in cases of relapse or refractory disease. It reviews the wide range of therapeutic options available to patients, including established treatments such as stem cell transplantation, immunomodulatory agents, and anti-CD38 antibodies. Additionally, some new kids on the block like bispecific T-cell therapy (BITE) CAR-T cellular therapy, and antibody-drug conjugates. The presentation also addresses the management of side effects specifically associated with BITEs and CAR-T therapies.